Figure 5From: Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis The cost-effectiveness acceptability curves showing the probabilities of net benefits achieved by the Gefitinib strategy compared to the Control strategy at different WTP thresholds in advanced NSCLC patients. Back to article page